hcv product sale still remain concern
maintain rate sell downgrad tp
estim tp
basi non ep earn multipl
upsid potenti expect
top-lin revenu declin
estim tp base forward price-to-earnings multipl
howev current price-to-earnings lower
forward price-to-earnings multipl gilead earn
decreas everi quarter due lower sale hcv product
gilead stock price decreas due poor perform
everi quarter expect stock fall
total revenu declin declin
revenu due lower hcv product revenu declin
y/i hiv/hbv product revenu
increas abl off-set
declin revenu hcv product
quarter gilead launch biktarvi hiv
product compani expect becom number one
single-tablet regimen futur
recent gilead made collabor verili life scienc
use verili immunoscap platform identifi better
understand immunolog basi three common
inflammatori bowel diseas lupus-rel diseas
collabor inc sangamo use
sangamo zinc finger nucleas technolog platform
develop next-gener ex vivo cell therapi oncolog
compani namegilead scienc inc tickergildstock ratingbuyunchangedindustri viewoverweightpositivepric jun week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth june
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
net incom decreas compar
ep decreas
compar non-gaap ep
decreas compar
gilead expect grow futur base grow
hiv busi led launch biktarvi increas
momentum cell therapi busi potenti
opportun emerg area nash
gilead chang guidanc expect
net product sale rang
ep impact non- adjust
expect
gilead stock price seen massiv declin due lower
sale volum hcv product gilead earn
fall everi quarter therefor price-to-earnings current
trade average stdev price-to-earnings went average
stdev averag price-to-earnings
face declin revenu quarter quarter due
lower hcv product sale abl recov
declin due increas competit acquir kite
pharma collabor verili life scienc
april still remain cautiou stock
start show sign growth give sell
rate stock downgrad tp
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend yield n/a pay-out dividend date jun ex-dividend date jun last split factor new per last split date jan inform gilead scienc inc june
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper oper profit interest income- incom special charges- interest incom minor incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli june
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri stock- total total total liabil stock actual annual actual quarterli balanc sheet item gilead scienc inc june
provid oper activ decreas compar
decreas due tax payment relat first annual instal tax
reform transit tax lower product sale
provid invest activ increas compar
due higher proce matur market secur
use financ activ compar increas cash
use financ activ due repay term loan borrow connect
acquisit kite higher repurchas common stock
defer incom oper gains- increas decreas increas decreas current assets- decreas increas decreas increas current decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant equipment- net invest financ activitiesissu issuanc capit repurchas capit payment financ charg net- discontinu financ activities- net financ net floweffect exchang rate net chang begin end june
gilead total revenu decreas compar
decreas revenu due lower hcv product
sale hcv product sale decreas due lower sale harvoni
sovaldi across major market lower sale epclusa
due increas competit
cost good sold increas compar
increas due amort expens
relat intang asset acquir connect
kite acquisit increas partial off-set lower cost
efavirenz compon atripla result termin
collabor arrang bristol-my squibb compani decemb
gross margin declin compar
declin due chang product mix
 expens increas compar
increas due stock base compens
expens associ gilead acquisit kite pharma inc non-gaap
 expens decreas compar
decreas due impact gilead purchas fda
sg expens increas compar
non-gaap sg expens increas
compar increas expens due
follow factor stock base compens expens associ
gilead acquisit kite pharma inc higher cost associ product
launch biktarvi yescarta geograph expans increas
expens support growth gilead busi kite acquisit
interest expens increas compar
due issuanc aggreg princip amount senior
unsecur note term loan borrow connect
acquisit kite march term loan fulli repaid
decreas
compar
increas
compar
increas
compar
provis incom tax compar
effect tax rate compar
decreas effect tax rate due reduct
corpor tax rate result enact tax cut job act tax
reform decemb partial off-set chang
geograph mix earn
compar
net incom decreas compar
non-gaap net incom decreas
compar
gaap ep decreas compar
non-gaap ep decreas compar
gilead cash cash equival market secur
compar gilead gener oper
cash flow fulli repaid term loan borrow
connect gilead acquisit kite util stock repurchas
paid cash dividend gilead paid quarterli dividend per
share
gaap ep decreas
compar
decreas
compar
broadli product portfolio gilead divid categori
antivir product product
total product revenu decreas compar
due lower sale hcv product
total product revenu declin compar
decreas revenu due lower sale hcv
product partial off-set higher sale hiv hbv product
total revenu europ declin compar
decreas due lower harvoni sovaldi sale
volum result increas competit avail gener
viread truvada atripla
total revenu locat decreas
compar due lower sale japan
decreas
compar
due lower
sale hcv product
total revenu hcv
product decreas
y/i
compar
antivir product includ sale hiv chronic hepat hbv chronic
hepat hcv product total revenu antivir product decreas
compar decreas
revenu due lower sale hcv product
total revenu decreas compar
total revenu europ decreas
compar total intern revenu
hcv product includ epclusa harvoni vosevi sovaldi total revenu
hcv product decreas y/i compar
decreas due lower sale harvoni
sovaldi across major market lower sale epclusa unit
state result increas competit
total revenu hcv product declin
compar total revenu europ
decreas compar
total intern revenu
epclusa revenu compar
unit state decreas due lower averag net
sell price sale volum result increas competit partial
off-set shift market harvoni sovaldi
total revenu europ compar
europ increas due higher sale volum result
higher total market patient start shift market harvoni
sovaldi
harvoni revenu decreas compar
harvoni revenu
compar total revenu europ
compar total revenu locat
compar
decreas major market due lower sale volum result
increas competit shift market harvoni epclusa
total revenu sovaldi decreas compar
due lower sale volum driven shift market
sovaldi epclusa
total revenu hcv
product declin
compar
decreas
compar
hiv hbv product
total revenu hiv hbv product increas
compar increas due
continu uptak tenofovir alafenamid taf -base product
includ genvoya descovi odefsey
total revenu compar
total revenu europ compar
total revenu locat
compar
descovy-bas regimen hiv biktarvi descovi genvoya odefsey
biktarvi approv fda februari genvoya approv
fda european commiss novemb descovi
approv fda european commiss april odefsey
approv fda european commiss
total product revenu descovy-bas regimen
compar product account total
antivir product revenu
total revenu descovy-bas regimen
compar total revenu europ
compar increas major market
due higher sale volum patient shift away truvada-bas
total revenu biktarvi total revenu
descovi increas compar
total revenu genvoya increas
compar total revenu odefsey increas
compar
total revenu hiv
hbv product
increas
compar
total revenu
genvoya increas
compar
total
revenu odefsey
increas
compar
truvada-bas regimen hiv atripla complera/eviplera stribild
total product revenu truvada-bas regimen declin
compar account
total antivir product revenu
total revenu truvada-bas regimen
compar unit state decreas
due lower sale volum result continu uptak
descovy-bas regimen partial off-set increas usag truvada
pre-exposur prophylaxi prep
total revenu europ compar
total revenu locat
compar europ decreas due lower
sale volum result avail gener truvada atripla
continu uptak descovy-bas regimen
product includ yescarta letairi ranexa ambisom total
revenu increas compar
total revenu yescarta sinc approv
total revenu letairi compar
letairi expect face gener competit unit state
start juli
ranexa revenu increas compar
ambisom revenu increas compar
total product revenu
truvada-bas
regimen declin
compar
account
total
total revenu
yescarta
sinc approv
revenu increas
compar
pipelin mileston anticip
biktarvy- approv februari expect
approv eu
vesatolimod expect complet phase studi hiv cure
capsid inhibitor initi phase studi
gs- initi phase studi
descovy- complet phase studi prep
initi phase studi line dlbcl
approv eu aggress nhl
complet enrol phase anti- combo
complet enrol phase indol nhl
follow data
initi phase adult
complet enrol phase mcl
initi phase pediatr
initi phase cll
complet enrol phase studi anti-bcma mn
decis registr studi base phase data
complet phase studi mage solid tumor
file ind tcr target solid tumor
tirabrutinib- achiev endpoint phase combin
studi r/r cll
phase studi line
dlbcl
approv
eu aggress
nhl
endpoint phase
combin studi
r/r cll
pipelin mileston anticip
nash pbc psc ah
complet enrol phase studi ah
week data stellar phase studi nash
week data stellar phase studi nash
data phase psc
complet phase studi nash
data phase nash
initi phase studi selonsertib and/or
and/or patient advanc fibrosi due nash
interim data
interim futil analysi phase studi uc
complet phase studi ankylos spondyl
complet phase studi psoriat arthriti
data finch phase studi ra
data finch phase studi ra
data finch phase studi ra
complet enrol divers studi crohn diseas
data phase studi cutan lupu erythematosu
data phase studi sjogren syndrom
remdesivir complet phase studi ebola survivor
complet enrol
phase studi ah
ebola survivor
product pipelin updat
product pipelin updat announc gilead includ
hiv programs- present data confer retrovirus
opportunist infect includ announc
detail result phase studi evalu efficaci
safeti switch regimen contain abacavir dolutegravir
lamivudin mg biktarvi once-daili singl
tablet regimen virolog suppress adult hiv week
biktarvi found statist non-inferior
numer lower incid mild moder studi drug-rel advers
event treatment-emerg resist
result phase studi virolog suppress adult
women hiv infect evalu efficaci safeti switch
boost proteas inhibitor bpi boost elvitegravir-contain
regimen biktarvi on-going studi biktarvi found
statist non-inferior regimen contain bpi boost elvitegravir
demonstr treatment-emerg resist week
result preclin studi conduct collabor
research beth israel deaco medic center evalu
combin proprietari investig oral toll-lik receptor agonist
proprietari investig broadli neutral antibodi
part hiv erad strategi
fda approv biktarvi treatment infect
oncolog cell therapi program
announc world-wide collabor inc
sangamo use sangamo zinc finger nucleas technolog platform
develop next-gener ex vivo cell therapi oncolog
announc clinic trial collabor inc evalu
safeti efficaci investig combin yescarta
patient refractori larg b-cell lymphoma
treatment
collabor
platform
develop next-
therapi oncolog
tabl show pipelin product candid gilead
indic areaiiiiiiregistr capsid inibitor hivvesatolimod bnab hivliv agonist hbvselonsertib inhibitor nashalcohol fxr inhibitor nashoth remdesivirebolainflammation/respiratoryfilgotinib inhibitor rheumatoid arthritiscrohn diseaseulc colitisinflammatori diseasespresatovir fusion inhibitor inflammatori bowel inhibitor sjogren syndromelupusu eu regulatori submiss gilead scienc inc june
tabl show pipelin product candid gilead
trialind areaiiiiiihematology/oncologyyescarta pmbcl tfleuindol nhldlbcl allpediatr mage tumorandecaliximab mab inhibitor gastric cancersolid tumorentospletinib inhibitor heme malignanciestirabrutinib btk inhibitor b-cell malignanciesphas gilead use verili
identifi better
understand
immunolog basi
three common
bowel diseas lupus-
gilead collabor verili life scienc
inc verili life scienc llc alphabet compani
announc scientif collabor april gilead use verili
immunoscap platform identifi better understand immunolog
basi three common seriou inflammatori diseas rheumatoid arthriti
inflammatori bowel diseas lupus-rel diseas
first large-scal deploy immunoscap uniqu platform
gener immunolog data insight verili analyz biolog
sampl clinic diseas treatment respons data patient
particip current futur gilead clinic trial
three-year collabor repres broadest effort date
interrog activ specif subtyp immun cell better understand
diseas signatur treatment respons potenti guid futur
drug discoveri develop goal improv outcom
peopl live diseas
kite gilead compani collabor sangamo therapeut
kite gilead compani inc announc
compani enter world-wide collabor use sangamo zinc
finger nucleas zfn technolog platform develop next-
gener ex vivo cell therapi oncolog
term agreement sangamo receiv up-front payment
elig receiv potenti payment
aggreg across product util sangamo technolog base
achiev certain research develop regulatori success
sangamo would also receiv tier royalti sale potenti futur product
result collabor kite respons develop
manufactur commerci product collabor
respons agre upon expens incur sangamo
net product sale
expect
dilut ep impact
non-
adjust
gilead fulli repaid
borrow connect
gilead acquisit
kite ytd stock
perform
roe sale
growth
guidanc conclus
net product sale expect
dilut ep impact non- adjust
gilead total revenu decreas compar
decreas due lower product sale total product
revenu decreas due lower sale hcv
product hcv product sale decreas due lower sale harvoni sovaldi
across major market lower sale epclusa due
net incom decreas non-gaap net incom
decreas ep decreas
non-gaap ep decreas
gilead recent collabor verili life scienc use verili
immunoscap platform identifi better understand immunolog
basi three common seriou inflammatori diseas rheumatoid arthriti
inflammatori bowel diseas lupus-rel diseas
gilead gener oper cash flow fulli repaid
term loan borrow connect gilead acquisit kite
ytd stock perform roe sale growth
guidancenet product product gross tax ep impact non- june
non- reconcili
non- reconcili
non- reconcili
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
revenu growth fell ttm basi compar due
lower sale hcv product
gross margin decreas ttm basi compar due
increas cog
ep growth ttm basi compar due decreas
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth gilead scienc inc june
mrqgross mrqcog mrqoper mrqsg mrqnet mrqr sale gilead scienc inc june
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn mrqcapex salescap ex salesfre mrq ratio growth yoy oper growth yoy free growth yoy gilead scienc inc june
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per share- book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out ratio- day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item gilead scienc inc june
balanc sheet ratio
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas business- sale business- purchas sale issuanc repurchas net issuanc prefer stock- net issuanc dividends- net chang capit free june
gilead ep decreas past three year therefor price-to-earnings went averag price-to-earnings
price-to-earnings trade average stdev current price-to-earnings
reach average stdev forward price-to-earnings multipl gilead earn
decreas everi quarter due lower hcv product sale abl recov
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form reportedmartin john norbert john jame gayl robin olsen paul john institut holdersholdersharesd report outvalueblackrock vanguard group inc capit research global fmr parnassu invest price row associ northern trust top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard spdr etf vanguard institut fund-institut invest compani parnassu equiti powershar exhg trade fd tr-powershar qqq tr seri ishar nasdaq biotechnolog ishar vanguard growth june
developmentskit announc new data analys therapi patient blood cancer american societi clinic oncolog meetingkit agilead compani announc new analys zuma chimer antigen receptor cell therapi develop program present societi clinic oncolog annual meet inchicago result includ analys studi yescartain adult patient refractori larg b-cell lymphoma show respons statu may predict rate progression-fre surviv treatment respons consist across prior line therapi gilead galapago announc result filgotinib phase equat studi psoriat arthriti progress phase select studi ulcer colitisgilead scienc inc andgalapago nv announc random placebo-control phase equat studi filgotinib investig select inhibitor adult moder sever psoriat arthriti achiev primari endpoint improv sign symptom psoriat arthriti week gilead verili announc scientif collabor identifi understand immunolog molecular driver inflammatori diseasesgilead scienc inc andverili life scienc llc alphabet compani announc scientif collabor use verili immunoscap platform identifi better understand immunolog basi three common seriou inflammatori diseas rheumatoid arthriti inflammatori bowel diseas lupus-rel diseas gilead present data phase studi evalu women switch biktarvi bictegravir emtricitabin tenofovir alafenamid boost proteas inhibitor-bas regimen boost elvitegravir-contain regimengilead scienc inc announc result phase studi studi virolog suppress adult women hiv infect evalu efficaci safeti switch boost proteas inhibitor bpi boost elvitegravir-contain regimen biktarvi once-daili singl tablet regimen on-going studi biktarvi found statist non-inferior regimen contain bpi boost elvitegravir demonstr treatment-emerg resist week june gilead scienc inc june
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
sale growth ttm
basi
compar
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit gilead scienc inc june
consensu view analyst trend stock
forecast
compar
multipl
compar
gild avgfive-year growth forecast usdgrowth high day day day estim comparisongildindustri avg avgprice/earn yield june
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim
current qtr
next qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate gilead scienc inc june
incom statement
pipelin mileston anticip
product pipelin
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price dip announc result gilead revenu earn
drop miss analyst estim
stock increas gilead announc posit news regard product pipelin recent
gilead stock momentum last one year volatil high
low
stock given return last one year
gilead stock price show decreas trend past three year due decreas revenu
earn trade around juli gradual decreas may
august volum share trade almost doubl past two
month year
gilead revenu declin due lower product sale hcv product still
abl recov situat gilead launch biktarvi hiv product quarter
expect product near futur still maintain sell rate product
downgrad tp previou tp achiev quarter stock price
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
